The trial looked at how JNJ-3989, a small-interfering RNA medication, affected individuals with chronic hepatitis B. JNJ-3989 was administered subcutaneously at dosages of 40 mg, 100 mg, and 200 mg every four weeks in conjunction with nucleotide analogs. The major aim was to determine the percentage of patients who satisfied the criteria for discontinuing nucleotide analogs, which included normal liver enzymes, undetectable HBV DNA, and low HBsAg levels. According to the findings, 16% of patients on the 100 mg dosage and 19% of patients on the 200 mg dosage satisfied these criteria, compared to only 2% in the control group. While no patients had a functional cure, the majority of patients who received JNJ-3989 showed significant decreases in HBsAg levels.

To know more: About the original article click here.